Zoledronic acid treatment for cancerous bone metastases: A phase IV study in Taiwan

Po Hui Chiang, Hwei Chung Wang, Yuen Liang Lai, Shin Cheh Chen, Wayne Yen-Hwa, Chit Kheng Kok, Yen Chuan Ou, Jen Shen Huang, Tzu Chuan Huang, Tsu Yi Chao

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim of study: To investigate the features, adverse effects, bone marker changes in patients with breast cancer, prostate cancer, and multiple myeloma with bone metastases under Zometa® therapy. Materials and Methods: This post-marketing study included 414 Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, or multiple myeloma who received Zometa® for 48 weeks. The patients′ characteristics, medication and adverse events were recorded, meanwhile changes in four serum bone metabolic markers and pain reduction were assessed every three months for one year. Results: A total of 3,711 doses of Zometa® were infused, accounting for 294.5 patient-years. Adverse events occurred in 9.4% of patients, with bone pain, insomnia, constipation, and pyrexia as the most frequently reported. There was no osteonecrosis of the jaw. The incidence of skeletal-related events decreased significantly from 44.9% to 18.8%. Serum NTx, BAP, and TRACP5b steadily decreased to nadir at six months, but serum OPG was persistently elevated until the end of one year. The average decrease in pain score was 14.1, 14.3, and 16.7 for prostate cancer, breast cancer, and multiple myeloma patients, respectively. Conclusion: Zometa® can be safely administered in Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, and multiple myeloma. There are concomitant decreases in skeletal-related events and bone pain.

Original languageEnglish
Pages (from-to)653-659
Number of pages7
JournalJournal of Cancer Research and Therapeutics
Volume9
Issue number4
DOIs
Publication statusPublished - 2013

Fingerprint

zoledronic acid
Taiwan
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Multiple Myeloma
Breast Neoplasms
Pain
Therapeutics
Serum
Osteonecrosis
Sleep Initiation and Maintenance Disorders
Constipation
Marketing
Jaw

Keywords

  • bone marker
  • Bone metastases
  • osteonecrosis of the jaw
  • skeletal-related event
  • Zometa

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Zoledronic acid treatment for cancerous bone metastases : A phase IV study in Taiwan. / Chiang, Po Hui; Wang, Hwei Chung; Lai, Yuen Liang; Chen, Shin Cheh; Yen-Hwa, Wayne; Kok, Chit Kheng; Ou, Yen Chuan; Huang, Jen Shen; Huang, Tzu Chuan; Chao, Tsu Yi.

In: Journal of Cancer Research and Therapeutics, Vol. 9, No. 4, 2013, p. 653-659.

Research output: Contribution to journalArticle

Chiang, PH, Wang, HC, Lai, YL, Chen, SC, Yen-Hwa, W, Kok, CK, Ou, YC, Huang, JS, Huang, TC & Chao, TY 2013, 'Zoledronic acid treatment for cancerous bone metastases: A phase IV study in Taiwan', Journal of Cancer Research and Therapeutics, vol. 9, no. 4, pp. 653-659. https://doi.org/10.4103/0973-1482.126471
Chiang, Po Hui ; Wang, Hwei Chung ; Lai, Yuen Liang ; Chen, Shin Cheh ; Yen-Hwa, Wayne ; Kok, Chit Kheng ; Ou, Yen Chuan ; Huang, Jen Shen ; Huang, Tzu Chuan ; Chao, Tsu Yi. / Zoledronic acid treatment for cancerous bone metastases : A phase IV study in Taiwan. In: Journal of Cancer Research and Therapeutics. 2013 ; Vol. 9, No. 4. pp. 653-659.
@article{9ce5fe85cfb34642b855c0d33b9dae70,
title = "Zoledronic acid treatment for cancerous bone metastases: A phase IV study in Taiwan",
abstract = "Aim of study: To investigate the features, adverse effects, bone marker changes in patients with breast cancer, prostate cancer, and multiple myeloma with bone metastases under Zometa{\circledR} therapy. Materials and Methods: This post-marketing study included 414 Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, or multiple myeloma who received Zometa{\circledR} for 48 weeks. The patients′ characteristics, medication and adverse events were recorded, meanwhile changes in four serum bone metabolic markers and pain reduction were assessed every three months for one year. Results: A total of 3,711 doses of Zometa{\circledR} were infused, accounting for 294.5 patient-years. Adverse events occurred in 9.4{\%} of patients, with bone pain, insomnia, constipation, and pyrexia as the most frequently reported. There was no osteonecrosis of the jaw. The incidence of skeletal-related events decreased significantly from 44.9{\%} to 18.8{\%}. Serum NTx, BAP, and TRACP5b steadily decreased to nadir at six months, but serum OPG was persistently elevated until the end of one year. The average decrease in pain score was 14.1, 14.3, and 16.7 for prostate cancer, breast cancer, and multiple myeloma patients, respectively. Conclusion: Zometa{\circledR} can be safely administered in Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, and multiple myeloma. There are concomitant decreases in skeletal-related events and bone pain.",
keywords = "bone marker, Bone metastases, osteonecrosis of the jaw, skeletal-related event, Zometa",
author = "Chiang, {Po Hui} and Wang, {Hwei Chung} and Lai, {Yuen Liang} and Chen, {Shin Cheh} and Wayne Yen-Hwa and Kok, {Chit Kheng} and Ou, {Yen Chuan} and Huang, {Jen Shen} and Huang, {Tzu Chuan} and Chao, {Tsu Yi}",
year = "2013",
doi = "10.4103/0973-1482.126471",
language = "English",
volume = "9",
pages = "653--659",
journal = "Journal of Cancer Research and Therapeutics",
issn = "0973-1482",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Zoledronic acid treatment for cancerous bone metastases

T2 - A phase IV study in Taiwan

AU - Chiang, Po Hui

AU - Wang, Hwei Chung

AU - Lai, Yuen Liang

AU - Chen, Shin Cheh

AU - Yen-Hwa, Wayne

AU - Kok, Chit Kheng

AU - Ou, Yen Chuan

AU - Huang, Jen Shen

AU - Huang, Tzu Chuan

AU - Chao, Tsu Yi

PY - 2013

Y1 - 2013

N2 - Aim of study: To investigate the features, adverse effects, bone marker changes in patients with breast cancer, prostate cancer, and multiple myeloma with bone metastases under Zometa® therapy. Materials and Methods: This post-marketing study included 414 Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, or multiple myeloma who received Zometa® for 48 weeks. The patients′ characteristics, medication and adverse events were recorded, meanwhile changes in four serum bone metabolic markers and pain reduction were assessed every three months for one year. Results: A total of 3,711 doses of Zometa® were infused, accounting for 294.5 patient-years. Adverse events occurred in 9.4% of patients, with bone pain, insomnia, constipation, and pyrexia as the most frequently reported. There was no osteonecrosis of the jaw. The incidence of skeletal-related events decreased significantly from 44.9% to 18.8%. Serum NTx, BAP, and TRACP5b steadily decreased to nadir at six months, but serum OPG was persistently elevated until the end of one year. The average decrease in pain score was 14.1, 14.3, and 16.7 for prostate cancer, breast cancer, and multiple myeloma patients, respectively. Conclusion: Zometa® can be safely administered in Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, and multiple myeloma. There are concomitant decreases in skeletal-related events and bone pain.

AB - Aim of study: To investigate the features, adverse effects, bone marker changes in patients with breast cancer, prostate cancer, and multiple myeloma with bone metastases under Zometa® therapy. Materials and Methods: This post-marketing study included 414 Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, or multiple myeloma who received Zometa® for 48 weeks. The patients′ characteristics, medication and adverse events were recorded, meanwhile changes in four serum bone metabolic markers and pain reduction were assessed every three months for one year. Results: A total of 3,711 doses of Zometa® were infused, accounting for 294.5 patient-years. Adverse events occurred in 9.4% of patients, with bone pain, insomnia, constipation, and pyrexia as the most frequently reported. There was no osteonecrosis of the jaw. The incidence of skeletal-related events decreased significantly from 44.9% to 18.8%. Serum NTx, BAP, and TRACP5b steadily decreased to nadir at six months, but serum OPG was persistently elevated until the end of one year. The average decrease in pain score was 14.1, 14.3, and 16.7 for prostate cancer, breast cancer, and multiple myeloma patients, respectively. Conclusion: Zometa® can be safely administered in Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, and multiple myeloma. There are concomitant decreases in skeletal-related events and bone pain.

KW - bone marker

KW - Bone metastases

KW - osteonecrosis of the jaw

KW - skeletal-related event

KW - Zometa

UR - http://www.scopus.com/inward/record.url?scp=84894427695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894427695&partnerID=8YFLogxK

U2 - 10.4103/0973-1482.126471

DO - 10.4103/0973-1482.126471

M3 - Article

C2 - 24518712

AN - SCOPUS:84894427695

VL - 9

SP - 653

EP - 659

JO - Journal of Cancer Research and Therapeutics

JF - Journal of Cancer Research and Therapeutics

SN - 0973-1482

IS - 4

ER -